Scisparc successfully completed the development of its proprietary drug candidate sci-110 for its upcoming phase iib study in tourette syndrome

Tel aviv, israel, june 29, 2022 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (the "company" or "scisparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it has successfully completed the development of its top-tier drug candidate sci-110 to be used in its upcoming multinational, multicenter, phase iib study for tourette syndrome ("ts").
SPRC Ratings Summary
SPRC Quant Ranking